We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 696

Exploring the relationship between price and competition among physician practices

  • Sheppard Mullin Richter & Hampton LLP
  • -
  • USA
  • -
  • October 29 2014

The latest from the Journal of the American Medical Association (JAMA) is a thematic issue organized around a prominent topic in healthcare: price

Reverse payment settlements in the pharmaceutical industry after Actavis

  • Cohen & Gresser LLP
  • -
  • USA
  • -
  • October 24 2014

In Actavis, the Supreme Court held that reverse payment agreements should be reviewed by the rule-of-reason antitrust standard Reverse payment

Connecticut law imposes new merger regulations on physician combinations

  • Dickinson Wright PLLC
  • -
  • USA
  • -
  • October 21 2014

On October 1, a first-of-its-kind law became effective in Connecticut that requires group medical practices and hospitals in that state to provide

Connecticut requires pre-acquisition notice of physician practices and hospitals

  • McGuireWoods LLP
  • -
  • USA
  • -
  • October 20 2014

Effective October 1, 2014, Connecticut requires prior notification of any transaction that will result in a material change of the business or

Connecticut is latest state to expand healthcare antitrust enforcement

  • Proskauer Rose LLP
  • -
  • USA
  • -
  • October 15 2014

Under new Connecticut healthcare legislation, which took effect October 1, 2014, parties to transactions that result in a "material change to the

Provider competition matterseven for “reference pricing”

  • Baker & Hostetler LLP
  • -
  • USA
  • -
  • October 9 2014

In a recent blog post, three Federal Trade Commission (FTC) economists splashed some cold water on advocates of “reference pricing” that seem to

New York AG accuses pharmaceutical companies of product hopping

  • McGuireWoods LLP
  • -
  • USA
  • -
  • October 7 2014

On September 15, in New York v. Actavis PLC et al., New York State Attorney General Eric Schneiderman filed an antitrust suit against Actavis PLC and

Will Namenda IR withdrawal force a legal switch on product hopping?

  • Fenwick & West LLP
  • -
  • USA
  • -
  • October 3 2014

On September 15, 2014, New York Attorney General Eric Schneiderman filed an anti-trust lawsuit against the specialty pharmaceutical company Forest

Health Law Insight September 2014 State update New York

  • McCarter & English LLP
  • -
  • USA
  • -
  • October 2 2014

New York State’s Department of Health proposed regulations for entities to obtain a Certificate of Public Advantage (COPA) under Public Health Law

Sham-wow! antitrust liability may attach to sham administrative petitions

  • McDermott Will & Emery
  • -
  • USA
  • -
  • October 1 2014

Addressing whether the “sham” exception to Noerr-Pennington immunity is limited to sham litigation in courts, the U.S. Court of Appeals for the